Your browser is no longer supported. Please, upgrade your browser.
Settings
AKTX Akari Therapeutics, Plc daily Stock Chart
AKTX [NASD]
Akari Therapeutics, Plc
Index- P/E- EPS (ttm)-0.78 Insider Own57.08% Shs Outstand20.40M Perf Week-2.04%
Market Cap39.17M Forward P/E- EPS next Y-0.33 Insider Trans0.00% Shs Float10.35M Perf Month5.25%
Income-12.90M PEG- EPS next Q-0.15 Inst Own3.40% Short Float1.77% Perf Quarter-4.00%
Sales- P/S- EPS this Y62.30% Inst Trans-36.46% Short Ratio0.49 Perf Half Y-15.79%
Book/sh0.22 P/B8.73 EPS next Y23.80% ROA-158.50% Target Price7.50 Perf Year8.47%
Cash/sh0.31 P/C6.22 EPS next 5Y- ROE-716.40% 52W Range1.56 - 9.20 Perf YTD22.29%
Dividend- P/FCF- EPS past 5Y42.60% ROI- 52W High-79.13% Beta-2.80
Dividend %- Quick Ratio1.70 Sales past 5Y- Gross Margin- 52W Low23.08% ATR0.12
Employees13 Current Ratio1.70 Sales Q/Q- Oper. Margin- RSI (14)51.09 Volatility5.51% 5.98%
OptionableNo Debt/Eq0.00 EPS Q/Q40.40% Profit Margin- Rel Volume0.34 Prev Close1.91
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume374.00K Price1.92
Recom1.50 SMA201.00% SMA503.55% SMA200-17.44% Volume127,694 Change0.52%
Jan-04-19Upgrade B. Riley FBR Neutral → Buy $2.50 → $3
Feb-08-18Initiated B. Riley FBR, Inc. Neutral $3
Sep-22-17Upgrade William Blair Mkt Perform → Outperform
May-31-17Upgrade Chardan Capital Markets Sell → Neutral $6
Apr-17-17Reiterated Chardan Capital Markets Sell $6.50 → $5
Jul-11-16Initiated Chardan Capital Markets Sell $5
Dec-02-19 08:30AM  Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting GlobeNewswire
Nov-18-19 06:09AM  What Kind Of Shareholder Owns Most Akari Therapeutics, Plc (NASDAQ:AKTX) Stock? Simply Wall St.
Nov-04-19 08:33AM  Akari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress GlobeNewswire
Oct-14-19 08:37AM  Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I/II AKC Trial GlobeNewswire
Oct-10-19 08:45AM  Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress GlobeNewswire -12.44%
07:31AM  The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO Benzinga
Oct-06-19 05:15PM  The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck Benzinga
Sep-19-19 06:54AM  How Much Cash Is Left In The Bank For Akari Therapeutics, Plc (NASDAQ:AKTX)? Simply Wall St.
Sep-18-19 08:00AM  Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference GlobeNewswire
Sep-16-19 10:29AM  Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease Zacks
Sep-13-19 08:00AM  Akari Therapeutics Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid GlobeNewswire
Sep-04-19 10:02AM  Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More Zacks
Sep-03-19 07:00AM  Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September GlobeNewswire -8.17%
Sep-02-19 09:17AM  Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease Zacks
Aug-30-19 12:51PM  A Look At Benzinga Pro's Most-Searched Tickers For August 30, 2019 Benzinga +7.77%
11:39AM  The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation Benzinga
10:54AM  Akari's 2-Day Rally: What You Need To Know Benzinga
07:27AM  Akari Therapeutics shares soar 13% premarket after FDA grants Orphan Drug designation to nomacopan MarketWatch
07:00AM  Akari Therapeutics Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA) GlobeNewswire
Aug-29-19 08:06AM  Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress GlobeNewswire +12.21%
Aug-15-19 11:55AM  A Look At Benzinga Pro's Most-Searched Tickers For August 15, 2019 Benzinga -29.79%
Aug-14-19 12:27PM  Biopharma News: Why Akari Therapeutics (AKTX) Stock Is Soaring Today InvestorPlace +62.22%
08:58AM  Akari Therapeutics' stock rockets on heavy volume after FDA grants nomacopan 'Fast Track' designation MarketWatch
08:00AM  Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) GlobeNewswire
Aug-09-19 08:30AM  Akari Therapeutics announces new data demonstrating synergistic benefits of nomacopans bifunctional C5 and LTB4 inhibitory activity in pemphigoid disease GlobeNewswire
Jul-31-19 09:57AM  Akari Therapeutics Announces Oral Presentation of Nomacopan Phase II Data in Patients with Bullous Pemphigoid at the 28th European Academy of Dermatology and Venereology (EADV) Congress, October 9-13, 2019 GlobeNewswire
Jul-17-19 03:00PM  Before You Buy Akari Therapeutics, Plc (NASDAQ:AKTX), Consider Its Volatility Simply Wall St.
Jul-04-19 08:35AM  Alexion's Ultomiris Receives EU Approval for PNH in Adults Zacks
Jun-28-19 09:22AM  Akari Therapeutics, Plc Announces $4.5 Million Registered Direct Offering GlobeNewswire
08:45AM  Alexion Receives FDA Approval for Label Expansion of Soliris Zacks
Jun-21-19 11:05AM  Alexion's sBLA for Ultomiris Gets Priority Review From FDA Zacks
Jun-20-19 09:35AM  Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study Zacks -5.48%
Jun-19-19 11:24AM  Akari's Lead Candidate Found Safe, Effective In Treating Eye Inflammation Benzinga
07:39AM  Akari Therapeutics Nomacopan Demonstrates Positive Early Safety and Efficacy in Phase I/II Clinical Study in Moderate-to-Severe Atopic Keraconjunctivitis (AKC) GlobeNewswire
May-29-19 07:45AM  Akari Therapeutics Reports First Quarter 2019 Financial Results And Highlights Recent Clinical Progress GlobeNewswire -7.46%
Apr-29-19 07:30AM  FDA Events Put Healthcare Stocks In The Headlines: Here's One That No One's Talking About Yet ACCESSWIRE
Apr-26-19 08:48AM  Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases GlobeNewswire -10.97%
Apr-24-19 08:09AM  The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova Benzinga
Apr-23-19 04:01PM  Akari Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights GlobeNewswire +15.82%
02:05PM  Positive News in The Biotech, Social Media, Financial & Cannabis Sectors Help the Market Towards New Highs ACCESSWIRE
11:04AM  Microcap Biotech Akari Rallies On Coversin Trial Results Benzinga
08:30AM  Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid GlobeNewswire
Mar-27-19 04:15PM  Akari Therapeutics to Provide Update on its Eye Disease Program During Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting GlobeNewswire -5.00%
Mar-18-19 02:30PM  These Tech Stocks Could Test March Highs ACCESSWIRE +12.01%
Mar-14-19 10:06AM  What Kind Of Shareholders Own Akari Therapeutics, Plc (NASDAQ:AKTX)? Simply Wall St.
07:47AM  The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering Benzinga
Mar-13-19 02:35PM  These 4 Tech Stocks Are On The Rise On Wednesday (3/13/19) ACCESSWIRE +224.16%
10:35AM  Akari Therapeutics' stock rockets on massive volume after 'successful' pre-IND FDA meeting MarketWatch
08:30AM  Positive FDA Meeting Outlines Path Ahead for Akari Therapeuticss Coversin in Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) GlobeNewswire
Feb-21-19 08:30AM  Factors of Influence in 2019, Key Indicators and Opportunity within EnLink Midstream, Pepsico, Arista Networks, Maiden, GCI Liberty, and Akari Therapeutics New Research Emphasizes Economic Growth GlobeNewswire
Feb-04-19 12:45PM  Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up Zacks
Jan-29-19 11:10AM  Alexion's Ultomiris Meets Primary Endpoint in aHUS Study Zacks
Dec-26-18 11:19AM  What You Must Know About Akari Therapeutics, Plcs (NASDAQ:AKTX) Beta Value Simply Wall St.
Nov-30-18 04:05PM  Akari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate Coversin GlobeNewswire
Nov-15-18 09:00AM  Akari Announces Coversin Data to be Presented at 2018 Complement-Based Drug Development Summit GlobeNewswire
06:50AM  Akari Announces Third Quarter 2018 Financial Results and Business Highlights GlobeNewswire
Oct-25-18 08:55AM  Factors of Influence in 2018, Key Indicators and Opportunity within Intersect ENT, Akari Therapeutics, Ampio Pharmaceuticals, Virtusa, Umpqua, and Hamilton Lane New Research Emphasizes Economic Growth GlobeNewswire
Sep-30-18 07:30AM  Akari Therapeutics Announces New Clinical Data in Post-Transplant Thrombotic Microangiopathies. Data Supports Akaris Ongoing Clinical Expansion into a Range of Orphan Autoinflammatory Diseases That Are Either Mediated by Complement C5 or Have Synchronous LTB4 and C5 Activity GlobeNewswire
Sep-27-18 06:56AM  Akari Announces Second Quarter 2018 Financial Results and Business Highlights GlobeNewswire +11.97%
06:55AM  Akari Therapeutics Enters into a Securities Purchase Agreement for up to $20 Million with Aspire Capital Fund, LLC GlobeNewswire
Sep-25-18 07:00AM  Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-12-18 07:00AM  Akari Therapeutics Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous Pemphigoid, Highlighting Potential Advantages of Coversins bifunctional activity inhibiting both the Complement and Leukotriene Inflammatory Pathways GlobeNewswire +7.29%
Sep-04-18 08:30AM  Research Report Identifies Brady, Akari Therapeutics, MTGE Investment, Jones Lang LaSalle, New Relic, and Sorrento Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +18.09%
Aug-20-18 09:00AM  The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Akari Therapeutics, plc -- AKTX GlobeNewswire
Aug-17-18 07:00AM  Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials GlobeNewswire
Jun-15-18 08:00AM  Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association GlobeNewswire +8.99%
May-25-18 07:53PM  How Do Analysts See Akari Therapeutics Plc (NASDAQ:AKTX) Performing In The Years Ahead? Simply Wall St.
08:20AM  Market Trends Toward New Normal in Independent Bank, First Busey, American Public Education, The First Bancshares, Northfield, and Akari Therapeutics Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-21-18 08:00AM  Akari Therapeutics Receives Notice Related to Delay in 20-F Filing GlobeNewswire -6.84%
May-16-18 07:23PM  Should You Buy Akari Therapeutics Plc (NASDAQ:AKTX) Now? Simply Wall St.
Apr-16-18 07:20AM  Blog Exposure - Tetraphase Pharma Announced Data Presentations from IGNITE4 Study at 28th European Congress of Clinical Microbiology and Infectious Diseases ACCESSWIRE -5.74%
Apr-03-18 08:25AM  Analysis: Positioning to Benefit within ForeScout Technologies, CommerceHub, Newtek Business Services, Credit Acceptance, Akari Therapeutics, and Brady Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-21-18 03:50PM  Edited Transcript of AKTX earnings conference call or presentation 21-Mar-18 12:30pm GMT Thomson Reuters StreetEvents -6.13%
07:00AM  Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical Progress GlobeNewswire
Mar-16-18 08:00AM  Akari Therapeutics To Report Fourth Quarter and Full Year 2017 Financial and Operational Results and Host Conference Call on March 21, 2018 GlobeNewswire
Feb-07-18 04:30PM  Akari Therapeutics to Present at the Leerink Partners Global Healthcare Conference GlobeNewswire
Feb-06-18 07:00AM  Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials GlobeNewswire -10.59%
Feb-05-18 07:45AM  Market Trends Toward New Normal in NV5 Global, Akari Therapeutics, American Public Education, Twilio, Monroe Capital, and Jabil Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire -7.09%
Jan-23-18 08:00AM  Akari Therapeutics Strengthens Board with Two Senior Industry Appointments GlobeNewswire
Jan-10-18 08:42AM  Alder BioPharmaceuticals (ALDR) Jumps: Stock Rises 15.5% Zacks
Jan-08-18 08:46AM  CRISPR Therapeutics (CRSP) Jumps: Stock Rises 12.1% Zacks
Jan-05-18 04:29PM  Penumbra (PEN) Forms JV on Virtual Reality in Health Space Zacks -6.00%
08:56AM  Audentes Therapeutics (BOLD) Jumps: Stock Rises 14.9% Zacks
Jan-03-18 03:34PM  New Products Aid Boston Scientific, LOTUS Relaunch Lag Ails Zacks
01:40PM  Thermo Fisher Buys Phenom-World, Aids Analytical Instruments Zacks
03:04AM  Anika Therapeutics Receives FDA Nod for Bone Repair Therapy Zacks
Jan-02-18 09:09AM  PetMed Rides on Solid Reorders & New Orders Amid Competition Zacks
Dec-28-17 09:08AM  NutriSystem (NTRI) Adopts Multi-Brand Strategy for 2018 Zacks
Dec-26-17 08:51AM  Array BioPharma (ARRY) Looks Good: Stock Adds 9.6% in Session Zacks
Dec-21-17 08:58AM  Amarin Corporation (AMRN) in Focus: Stock Moves 8.9% Higher Zacks
Dec-13-17 08:57AM  Syros Pharmaceuticals (SYRS) in Focus: Stock Moves 12.7% Higher Zacks
08:47AM  Tenet Healthcare (THC) in Focus: Stock Moves 8.5% Higher Zacks
Dec-12-17 07:40AM  Wired News Akaris Phase-II COBALT Trial of Coversin in Patients with PNH Met the Primary Endpoint ACCESSWIRE -9.01%
Dec-11-17 08:41AM  Alexion (ALXN) in Focus: Stock Moves 7.2% Higher Zacks
Dec-08-17 04:05PM  Akari Therapeutics Announces Phase II COBALT trial of Coversin in Patients with PNH Met the Primary Endpoint GlobeNewswire
Dec-06-17 08:53AM  Why AveXis (AVXS) Could Be Positioned for a Slump Zacks
Dec-04-17 04:01PM  Akari Therapeutics to Host Investor and Analyst Event During the 59th American Society of Hematology Meeting GlobeNewswire
Dec-01-17 09:33AM  Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime Zacks
Nov-30-17 08:20AM  5 Affordable Breakout Stocks Offering Excellent Returns Zacks
08:00AM  Akari: December Coversin Update, Analysts Opinion and Catalysts ACCESSWIRE
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barre syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.